user

Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)

被引：0
|
作者：
Woerle, H. J. [1 ]
Neubacher, D. [2 ]
Patel, S. [3 ]
von Eynatten, M. [1 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[3] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2013年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S31 / S32
页数：2
相关论文
共 50 条
  • [31] Linagliptin for elderly patients with type 2 diabetes
    Shah, Rahman
    LANCET, 2014, 383 (9914): : 306 - 307
  • [32] Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)
    Hollander, Priscilla
    Golm, Gregory
    Carofano, Wendy
    Eldor, Roy
    Crutchlow, Michael
    Marcos, Michael
    Rendell, Marc
    Home, Philip
    Gallwitz, Baptist
    Rosenstock, Julio
    DIABETES, 2016, 65 : A238 - A238
  • [33] Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes (T2D): Outcomes by Body Mass Index (BMI)
    Shatskov, Alla
    Rezvani, Geoffrey
    Mansfield, Traci
    DIABETES, 2016, 65 : A299 - A299
  • [34] Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Nocturnal Hypoglycemia in the SoliMix Trial
    Mccrimmon, Rory J.
    Cheng, Alice Y.
    Fonseca, Vivian
    Choza, Ricardo
    Alessa, Thamer
    Alvarez, Agustina
    Souhami, Elisabeth
    Boss, Anders H.
    Picard, Pascaline
    Rosenstock, Julio
    DIABETES, 2021, 70
  • [35] Efficacy and Safety of Finerenone in Patients with CKD and T2D by Baseline Insulin Treatment
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Macisaac, Richard
    Wainstein, Julio
    Joseph, Amer
    Roessig, Lothar
    Scott, Charlie
    Bakris, George
    DIABETES, 2021, 70
  • [36] The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
    Liu, Jhih-Syuan
    Su, Sheng-Chiang
    Kuo, Feng-Chih
    Li, Peng-Fei
    Huang, Chia-Luen
    Ho, Li-Ju
    Chen, Kuan-Chan
    Liu, Yi-Chen
    Lin, Chih-Ping
    Cheng, An-Che
    Lee, Chien-Hsing
    Lin, Fu-Huang
    Hung, Yi-Jen
    Liu, Hsin-Ya
    Lu, Chieh-Hua
    Hsieh, Chang-Hsun
    MEDICINE, 2023, 102 (10) : E33167
  • [37] Safety and efficiency of the combination of basal insulin with liraglutide in hospitalised patients with type 2 diabetes
    Papantoniou, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S289 - S289
  • [38] Metabolic benefits of adding pioglitazone to patients with Type 2 diabetes (T2D) already optimized on insulin therapy
    Mattoo, V
    Eckland, D
    Widel, M
    Duran, S
    Fajardo, C
    Strand, J
    Knight, D
    Oakley, D
    Tan, M
    DIABETOLOGIA, 2004, 47 : A59 - A59
  • [39] Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
    von Websky, Karoline
    Reichetzeder, Christoph
    Hocher, Berthold
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 681 - 694
  • [40] Safety and Tolerability of Linagliptin and Metformin in Combination for Patients with Type 2 Diabetes Mellitus (T2DM)
    Ross, Stuart A.
    Haak, Thomas
    Patel, Sanjay
    Thiemann, Sandra
    Schumacher, Helmut
    Meinicke, Thomas
    DIABETES, 2014, 63 : A277 - A277
12345